The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer-In Reply
JAMA Oncol
.
2019 Oct 1;5(10):1512.
doi: 10.1001/jamaoncol.2019.2991.
Authors
Giacomo Bregni
1
,
Stefania Sciallero
1
,
Alberto Sobrero
1
Affiliation
1
Ospedale Policlinico San Martino Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
PMID:
31415059
DOI:
10.1001/jamaoncol.2019.2991
No abstract available